Erasca (ERAS) Investor Presentation - Slideshow

234 55 55 35 225 120 260 126 10 ERAS-3490 56 1,221 1,687 483 Erasca's naporafenib pan-RAFi could address unmet needs P P P Autophagy MAPK pathway ULK PI3K pathway RAS-GTP GRB2 SHP2 GAP GDP GTP P1 NF1 SOS1 RAF MEK PI3K AKT mTOR RAS-GDP EGFR/ Other FLT3 RTKs MYC GEF ERK naporafenib BRAF CRAF RAS Q61X Solid Tumors 157,000 NRASm Melanoma 54,000 NF1 Loss-of-Function 234,000 BRAF Class II/III Solid 55,000 11 | --- | --- | |--------------------------------------|------------| | Assay | Value (nM) | | Biochemical C ...